US-based Transpire Bio announced that it has opened an R&D facility in Shanghai, China with approximately 40 employees who will work on development of generic OINDPs for the UK, European, and Asian Pacific markets. Transpire notes that its “core R&D and manufacturing facilities remain firmly established in the United States” where the company opened its Florida headquarters and manufacturing facility in 2023.
Since mid-2025, Transpire has announced progress related to development of Suzhou Intragrand Pharma’s ITG-1052 PDE4 inhibitor as an inhaled therapy for IPF; Phase 1 development of an inhaled cannabidiol formulation; and regulatory submission for a generic of Trelegy Ellipta DPI. The company also recently announced the appointment of Ewan Livesey as its new Head of Business Development.
Transpire CEO Xian-Ming Zeng commented, “As Transpire Bio continues to execute its strategic plan of building a legacy as an innovator in inhalation-based therapies, we are pleased to announce the grand opening of our Shanghai R&D center. This team of inhalation scientists and device engineers will be focused on our next generation inhalation device platforms as well as generic substitutable and hybrid inhalation product candidates intended for markets in the EU, UK, and APAC regions, further expanding our ability to innovate and bring new therapeutic options to patients around the world.”
Read the Transpire Bio press release
